Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: Emphasis on the key role and responsibility of pathologists

Acta Gastro-Enterologica Belgica

Volumn 73, Issue 4, 2010, Pages 497-503

  Hoorens, A ^a   Jouret Mourin, A ^b   Sempoux, C ^b   Demetter, P ^c   de Hertogh, G ^d   Teugels, E ^e  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cetuximab; Colorectal cancer; Egfr; Kras mutation; Panitumumab

Indexed keywords

B RAF KINASE; CETUXIMAB; DNA; K RAS PROTEIN; MUCIN; PANITUMUMAB; PARAFFIN; TUMOR MARKER; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CARCINOGENESIS; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; DENATURING GRADIENT GEL ELECTROPHORESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA EXTRACTION; DRUG EFFICACY; FALSE NEGATIVE RESULT; FOLLOW UP; GENE AMPLIFICATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IMAGE ANALYSIS; MEDICAL SPECIALIST; METASTASIS; METASTATIC COLORECTAL CANCER; MOLECULAR DIAGNOSIS; MUTATION; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SINGLE STRAND CONFORMATION POLYMORPHISM; TISSUE FIXATION; TISSUE PRESERVATION; COLORECTAL TUMOR; GENETICS; HISTOLOGY; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79952132274     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. LEMMON M.A., SCHLESSINGER J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem. Sci., 1994, 19: 459-463.
2. YARDEN Y, SLIWKOWSKI M.X; Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2001, 2: 127-137.
3. BURGESS A.W., CHO H.S., EIGENBROT C., FERGUSON K.M., GARRETT T.P., LEAHY D.J., LEMMON M.A., SLIWKOWSKI M.X., WARD C.W., YOKOYAMA S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell, 2003, 12: 541-552.
4. ONO M., KUWANO M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res., 2006, 12: 7242-7251.
5. LOCKHART A.C., BERLIN J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol., 2005, 32: 52-60.
6. IQBAL S., LENZ H.J. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother. Pharmacol., 2004, 54 Suppl 1: S32-S39.
7. PEETERS M., BALFOUR J., ARNOLD D. Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment. Pharmacol. Ther., 2008, 28: 269-281.
8. HARDING J., BURTNESS B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc.), 2005, 41: 107-127.
9. HEINEMANN V., STINTZING S., KIRCHNER T., BOECK S., JUNG A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev., 2009, 35: 262-271.
10. FORRESTER K., ALMOGUERA C., HAN K., GRIZZLE W.E., PERUCHO M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature, 1987, 327: 298-303.
11. CAPELLA G., CRONAUER-MITRA S., PIENADO M.A., PERUCHO M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ. Health Perspect., 1991, 93: 125-131.
12. FEARON E.R. K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. J. Natl. Cancer Inst., 1993, 85: 1978-1980.
13. ALLEGRA C.J., JESSUP J.M., SOMERFIELD M.R., HAMILTON S.R., HAMMOND E.H., HAYES D.F., MC ALLISTER P.K., MORTON R.F., SCHILSKY R.L. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol., 2009, 27: 2091-2096.
14. JIMENO A., MESSERSMITH W.A., HIRSCH F.R., FRANKLIN W.A., ECKHARDT S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol., 2009, 27: 1130-1136.
15. WANG H.L., LOPATEGUI J., AMIN M.B., PATTERSON S.D. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv. Anat. Pathol., 2010, 17: 23-32.
16. WANG H.L., LOPATEGUI J., AMIN M.B., PATTERSON S.D: KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv. Anat. Pathol., 2010, 17: 23-32.
17. College of American Pathologists. Perspectives on Emerging Technologies: KRAS mutation testing for colorectal cancer (CRC). 2009.
18. MONZON F.A., OGINO S., HAMMOND M.E., HALLING K.C., BLOOM K.J., NIKIFOROVA M.N. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med., 2009, 133: 1600-1606.
19. PLESEC T.P., HUNT J.L. KRAS mutation testing in colorectal cancer. Adv. Anat. Pathol., 2009, 16: 196-203.
20. HUNT J.L., FINKELSTEIN S.D. Microdissection techniques for molecular testing in surgical pathology. Arch. Pathol. Lab. Med., 2004, 128: 1372-1378.
21. HUNT J.L. Molecular pathology in anatomic pathology practice: a review of basic principles. Arch. Pathol. Lab. Med., 2008, 132: 248-260.
22. VOGELSTEIN B., FEARON E.R., HAMILTON S.R., KERN S.E., PREISINGER A.C., LEPPERT M., NAKAMURA Y., WHITE R., SMITS A.M., BOS J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 1988, 319: 525-532.
23. JEN J., POWELL S.M., PAPADOPOULOS N., SMITH K.J., HAMILTON S.R., VOGELSTEIN B., KINZLER K.W. Molecular determinants of dysplasia in colorectal lesions. Cancer Res., 1994, 54: 5523-5526.
24. ZAUBER P., SABBATH-SOLITARE M., MAROTTA S.P., BISHOP D.T. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol. Pathol., 2003, 56: 137-140.
25. VAN KRIEKEN J.H., JUNG A., KIRCHNER T., CARNEIRO F., SERUCA R., BOSMAN F.T., QUIRKE P., FLEJOU J.F., PLATO H.T., DE HERTOGH G., JARES P., LANGNER C., HOEFLER G., LIGTENBERG M., TINIAKOS D., TEJPAR S., BEVILACQUA G., ENSARI A. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch., 2008, 453: 417-431.
26. HODA S.A., ROSEN P.P.: Contemporaneous H&E sections should be standard practice in diagnostic immunopathology. Am. J. Surg. Pathol., 2007, 31: 1627.
27. FRANKLIN W.A., HANEY J., SUGITA M., BEMIS L., JIMENO A., MESSERSMITH WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J. Mol. Diagn., 2010, 12: 43-50.
28. HOORENS A., DE RIDDER M., JOURET-MOURIN A., SEMPOUX C., CUVELIER C.A., NAGY N., DE HERTOGH G., GEBOES K., DEMETTER P.: Pathological assessment of the rectal cancer resection specimen. B.J.M.O., 2009, 3: 251-260.
29. MOLINARI F., MARTIN V., SALETTI P., DE D.S., SPITALE A., CAMPONOVO A., BORDONI A., CRIPPA S., MAZZUCCHELLI L., FRATTINI M. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br. J. Cancer, 2009, 100: 1087-1094.
30. OLIVEIRA C., VELHO S., MOUTINHO C., FERREIRA A., PRETO A., DOMINGO E., CAPELINHA AF., DUVAL A., HAMELIN R., MACHADO J.C., SCHWARTZ S JR., CARNEIRO F., SERUCA R. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene, 2007, 26: 158-163.
31. WALTHER A., JOHNSTONE E., SWANTON C., MIDGLEY R., TOMLINSON I., KERR D. Genetic prognostic and predictive markers colorectal cancer. Nat. Rev. Cancer, 2009, 9: 489-499.
32. TEJPAR S., IN'T VELD P., KOCKX M., BELGIAN WORKING GROUP MOLECULAR PATHOLOGY. Harmonization of molecular oncology testing in Belgium: introduction of KRAS testing for colorectal cancer. B.J.M.O., 2009, 3: 16-22.
33. GULLEY M.L., BRAZIEL R.M., HALLING K.C., HSI E.D., KANT J.A., NIKIFOROVA M.N., NOWAK J.A., OGINO S., OLIVEIRA A., POLESKY H.F., SILVERMAN L., TUBBS R.R., VAN D. V., VANCE G.H., VERSALOVIC J. Clinical laboratory reports in molecular pathology. Arch. Pathol. Lab. Med., 2007, 131: 852-863.
34. ROULEAU E., SPYRATOS F., DIEUMEGARD B., GUINEBRETIERE J.M., LIDEREAU R., BIECHE I. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. Br. J. Cancer, 2008, 99: 2100.
35. BAISSE B., BOUZOURENE H., SARAGA E.P., BOSMAN F.T., BENHATTAR J. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int. J. Cancer, 2001, 93: 346-352.
36. LOUPAKIS F., RUZZO A., CREMOLINI C., VINCENZI B., SALVATORE L., SANTINI D., MASI G., STASI I., CANESTRARI E., RULLI E., FLORIANI I., BENCARDINO K., GALLUCCIO N., CATALANO V., TONINI G., MAGNANI M., FONTANINI G., BASOLO F., FALCONE A., GRAZIANO F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer, 2009, 101: 715-721.